Oral cladribine in phase 3 trial.Serono Serono is a biotechnology company headquartered in Geneva, Switzerland. The company was founded in 1906 in Italy. A key step in its development was the discovery of a method of extracting urinary gonadotropins by Dr Piero Donini allowing the company to become a leader in the , who makes the disease-modifying drug, Rebif, launched a phase 3 study of oral cladribine cladribine /clad·ri·bine/ (kla´dri-ben) a purine antimetabolite used as an antineoplastic in the treatment of hairy cell leukemia. , a drug that reduces immune cell levels. The double-blind, placebo-controlled trial will involve 1,290 people with relapsing-remitting Relapsing-remitting A pattern of symptoms of multiple sclerosis in which symptomatic attacks occur that last 24 hours or more, followed by complete or almost complete improvement. Mentioned in: Multiple Sclerosis forms of MS over the next two years. (For more information, see: clinicaltrials.gov/ct/show/NCT00213135.) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion